Diagnostic and clinical importance of interleukin‐2 receptor alpha chain expression on non‐T‐cell acute leukaemia cells

Abstract

The expression of interleukin-2 receptors (IL-2R) was examined in 328 adult patients with non-T-cell (non-T) acute leukaemia and blast crisis of chronic myelocytic leukaemia (CML.BC) using two monoclonal antibodies, anti-Tac for IL-2R alpha chain (IL-2R alpha) and Mik beta 1 for IL-2R beta chain (IL-2R beta). Leukaemic cells in the following cases were positive for anti-Tac; 28/192 of acute myelocytic leukaemia (AML), 24/44 CML-BC, 4/28 CD19(+)CD10(-) acute lymphoblastic leukaemia (ALL), and 20/64 common ALL (c-ALL). IL-2R beta was not detected on leukaemic cells of any case examined. Eleven of IL-2R alpha(+) AML were derived from myelodysplastic syndrome. None of the IL-2R alpha positive leukaemic cells responded to exogenous recombinant human IL-2 (rhIL-2) in culture. In addition, IL-2R alpha expression on non-T leukaemic cells was closely correlated with coexpressing different lineage markers and the presence of the Philadelphia abnormality. Marked increase of serum soluble IL-2R alpha was demonstrated in the IL-2R alpha(+) patients examined. Clinically, the IL-2R alpha(+) patients showed significantly lower response to chemotherapy and poorer prognosis than IL-2R alpha(-) patients. Our results clearly indicate the diagnostic importance of IL-2R alpha expression in non-T acute leukaemia with a close relation to the particular cellular characteristics and the prognosis.

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

“…Using a large cohort of AML patients Յ 60 years of age who were treated on a single ECOG trial, we confirm data from smaller, retrospective studies [21][22][23] and demonstrate that CD25 antigen expression is associated with adverse outcome in AML. In addition, we reveal that CD25 expression adds independent adverse prognostic relevance to the integrated cytogenetic-mutational risk classification 26 in patients with genetically defined intermediate-risk or unfavorable-risk disease.…”

“…Previously published data from small retrospective studies have suggested an unfavorable impact of CD25. [21][22][23] In the largest group studied to date, 22 CD25 was an independent adverse factor for the achievement of complete remission (CR), OS, and relapse-free survival in 65 patients with AML who were Յ 60 years of age treated on protocols from the Hemato-Oncologie voor Volwassenen Nederland (HOVON) or Haemato Oncology Foundation for Adults in The Netherlands. CD25 expression was positively associated with the presence of internal tandem duplications in FLT3 (FLT3-ITD), 22,23 a known adverse prognostic factor in AML, 24 suggesting that CD25 might function as a surrogate marker for FLT3-ITD.…”

Acute basophilic leukemia: Case report

“…CD25, though characteristic is not specific for basophil lineage of blast cells. CD25 positivity has been observed in blast cells of CML and few cases of myeloblastic and BCR/ABL-positive lymphoblastic leukemia [24]. In the present case, the characteristic cytomorphological features, the myeloid immunophenotype of blast cells with distinct maturation pattern with CD25 and CD34 along with Philadelphia negativity on cytogenetic studies favored a diagnosis of basophilic leukemia and ruled out basophilic blast crisis of CML, ALL, and non-basophil lineage AML.…”

Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor α-chain predicts a poor prognosis

“…There were no other receptors that revealed a clinical relevance similar to IL2Ra expression. As previously described, 19,20 cellular characteristics of ALL cases with increased IL-2Ra levels would appear to indicate that such leukemias concentrate in common ALL because high levels of this receptor were closely associated with the expression of the B-lineage, CD13/33, CD34 and the presence of Ph. Indeed, most of the cases expressing high IL-2Ra belonged to this type of leukemia.…”